Leerink Partners analyst David Risinger has maintained their bullish stance on TECX stock, giving a Buy rating yesterday.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
David Risinger has given his Buy rating due to a combination of factors that highlight the potential of Tectonic Therapeutic’s ongoing trials. Despite the recent setbacks in the relaxin drug development field, particularly with the volenrelaxin trial conducted by another company, Tectonic Therapeutic’s approach differs significantly in its trial design and patient selection criteria. This distinction suggests that Tectonic may avoid the pitfalls encountered by others in the field.
Additionally, the anticipation of upcoming trial results for Tectonic’s TX45 in late 2026 provides a potential catalyst for the stock. The company’s strategic differences in trial execution and the potential for positive outcomes in their trials underpin Risinger’s confidence in the stock’s future performance. As a result, he maintains an optimistic outlook on Tectonic Therapeutic’s shares.
In another report released yesterday, Oppenheimer also initiated coverage with a Buy rating on the stock with a $80.00 price target.